Biopharma company AEON Biopharma goes public in SPAC deal
Priveterra Acquisition Corp., a special purpose acquisition company (SPAC) chaired by Robert Palmisano, has successfully completed its business combination with AEON Biopharma, a Phase 3 stage-ready biopharmaceutical company. The merger was initially announced in January 2023. AEON Biopharma is known for its focus on developing a proprietary botulinum toxin complex for the treatment of multiple […]